vidarabine phosphate and Minimal Disease, Residual

vidarabine phosphate has been researched along with Minimal Disease, Residual in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bénichou, J; Cazin, B; Delmer, A; Divine, M; Dreyfus, B; Dumontet, C; Eghbali, H; Feugier, P; Grosbois, B; Guibon, O; Jaubert, J; Leleu, X; Leporrier, M; Leprêtre, S; Mahé, B; Maloisel, F; Maloum, K; Tournilhac, O; Travade, P	1

Trials

1 trial(s) available for vidarabine phosphate and Minimal Disease, Residual

Article	Year
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. British journal of haematology, 2008, Volume: 143, Issue:1 Topics: Adult; Aged; Biomarkers; Creatinine; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine Phosphate	2008

Article

Year

High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.

British journal of haematology, 2008, Volume: 143, Issue:1

Topics: Adult; Aged; Biomarkers; Creatinine; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine Phosphate

2008